This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine
dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent
patients will be assigned equally to one of three medication conditions: placebo or the
Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or
40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase
periods of sustained abstinence substantially more than placebo. Performance on a set of
behavioral tasks of impulsivity will be analyzed as potential predictors of treatment
response.